Amazon intends to announce next week a new wave of layoffs, part of a plan to reduce 30,000 positions globally, according to sources cited by Reuters. The company has already eliminated 14,000 administrative positions in October, and the new wave of layoffs could begin on Tuesday, affecting divisions such as Amazon Web Services, retail, Prime Video, and human resources. If fully implemented, this reduction would represent nearly 10% of Amazon's corporate workforce, which numbers 1.58 million employees.
This would become the largest round of layoffs in the company's 30-year history, surpassing the restructuring of 27,000 jobs in 2022. Although Amazon previously mentioned that layoffs are influenced by the rise of artificial intelligence, CEO Andy Jassy emphasized that the reasons are more related to organizational culture and bureaucracy. Employees affected by layoffs will benefit from a 90-day period on the payroll to seek new jobs.
This would become the largest round of layoffs in the company's 30-year history, surpassing the restructuring of 27,000 jobs in 2022. Although Amazon previously mentioned that layoffs are influenced by the rise of artificial intelligence, CEO Andy Jassy emphasized that the reasons are more related to organizational culture and bureaucracy. Employees affected by layoffs will benefit from a 90-day period on the payroll to seek new jobs.
Sources
Latest News
08:06
The U.S. Treasury debt has reached $40.047 trillion, exceeding CBO estimates. The rapid increase in the deficit raises concerns in the financial markets.
07:59
The Washington Post: Russians withdraw billions from banks, fearing that Putin will confiscate their deposits to finance his war
07:46
Hungary: The construction of a riverbed threshold on the Danube has raised the water level by 15-20 cm, preventing the shutdown of the turbines at the Paks nuclear power plant.
07:45
Kiev was the target of a new attack with Russian ballistic missiles. At least six people have died and 12 have been injured.
07:37
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
See more news